Effects of Recovery Time during Magnetic Nanofluid Hyperthermia on the Induction Behavior and Efficiency of Heat Shock Proteins 72

Jung-tak Jang1, Jin Wook Jeoung2, Joo Hyun Park2, Won June Lee2, Yu Jeong Kim2, Jiyun Seon1, Minkyu Kim3, Jooyoung Lee3, Sun Ha Paek3,4, Ki Ho Park2 & Seongtae Bae1

In this study, we investigated the effects of recovery time during magnetic nanofluid hyperthermia (MNFH) on the cell death rate and the heat shock proteins 72 (HSP72) induction behavior in retinal ganglion cells (RGCs-5) to provide a possible solution for highly efficient ocular neuroprotection. The recovery time and the heat duration time during MNFH were systematically controlled by changing the duty cycle of alternating current (AC) magnetic field during MNFH. It was clearly observed that the cell death rate and the HSP72 induction rate had a strong dependence on the recovery time and the optimized recovery time resulted in maximizing the induction efficiency of HSP72. Controlling the recovery time during MNFH affects not only the cell death rate but also HSP72 induction rate. The cell death rate after MNFH was dramatically decreased by increasing the recovery time during MNFH. However, it was also found that the HSP72 induction rate was slightly decreased by increasing the recovery time. These results indicate that applying the appropriate or optimized recovery time during MNFH can improve the induction efficiency of HSP72 by minimizing the cell death caused by cytotoxic effects of heat.

Induction of “heat shock proteins (HSPs)”, particularly HSP70 or HSP72 families, in retinal ganglion cells (RGCs) or optic nerve head has been considered to be a potential clinical modality for ocular neuroprotection in glaucoma since its physiological effectiveness has been demonstrated from the damaged rat eyes1–3. Hyperthermia as well as various other stress conditions, such as hypoxia, infection, medication, and exposure of cells to ultraviolet light and trace metals, can induce HSPs, which are mediated by activation of nuclear so-called “heat shock factors (HSF)”4–8. Among the several stress conditions, HSPs induction via hyperthermia treatment has been paid considerable attention in the clinics because hyperthermia is expected to minimize the chemical or biological “side effects” and “toxic problems”9–11. For instance, some hyperthermia treatment methods such as whole body hyperthermia using a warming blanket and local hyperthermia using a laser diode or magnetic nanoparticles were employed to induce HSPs in both in-vivo and in-vitro environments, and their effectiveness in the induction of HSPs was successfully demonstrated12–18. In order to achieve a highly efficient ocular neuroprotection in glaucoma, HSPs should be induced with a high induction rate as well as a low cell death rate in RGCs. However, although the above different hyperthermia treatment methods successfully induced HSPs, a low induction efficiency of HSPs due to a high cell death rate caused by the cytotoxic effects of heat on the cells was revealed as a critical challenge for future clinical applications. It was reported that the cells undergo a “rapid mode of cell death” when they are exposed to heat (hyperthermia or heating environments)19. In addition, it was observed that hyperthermia can induce microscopically detectable damage to the mitotic apparatus20. This damage results in inefficient mitosis and consecutive polyploidy. Fortunately, however, the cytotoxic effects of hyperthermia on the
cells have been shown to be biologically related with the exposure time (heat duration time) and intensity of the heat. Therefore, it is expected that the cell death rate can be minimized by controlling the intensity of the heat and its duration time in cells during hyperthermia, thereby improving the induction efficiency of HSPs.

In this study, we systematically controlled the ratio of the recovery time ($\tau_R$) to the heat duration time ($\tau_H$) of AC magnetic field (or AC heating stress) during magnetic hyperthermia to explore the effects of recovery time on the induction efficiency behavior of HSP72 in RGCs-5 for ocular neuroprotection in future glaucoma clinics. Magnetic nanofluid hyperthermia (MNFH) with tailored Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$ (T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$) superparamagnetic nanoparticles (SPNPs), which have a good electrical field absorption and a large power loss (200–500 W/m$^3$) at a low frequency (<100 KHz)$^{21}$, was employed as a hyperthermia modality to effectively control the $\tau_R$ and $\tau_H$ of the AC magnetic field during the HSPs induction process in RGCs-5 (Fig. 1a). In order to control the ratio of $\tau_R$ to $\tau_H$ of the AC magnetic field, the duty cycle (D) value of the applied AC magnetic field was systematically varied from 0.25 (25%) to 1 (100%) during MNFH (Fig. 1b). The induction behavior of HSP72 including the induction rate, the induction efficiency, and the cell death characteristics during HSPs induction process were studied by changing the $\tau_R$ during MNFH. The optimal D value (or the ratio of the $\tau_R$ to the $\tau_H$) was empirically investigated.

**Results and Discussion**

T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$ nanoparticles were prepared using a modified one-pot thermal decomposition method, which includes metal precursors and reductant in the presence of surfactants and solvent. As can be clearly seen in Fig. 2a, the synthesized T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$ nanoparticles had a spherical (round) shape with a mean particle (core) size of 6.5 nm ± 0.78 nm. In addition, as shown in Fig. 2b, high-resolution transmission electron microscopy (HR-TEM) analysis confirmed that the synthesized T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$ nanoparticles have a highly oriented typical cubic spinel structure with (400) and (220) preferred lattice planes. Crystal structure was determined using an X-ray diffractometer (XRD), and doping level of Mn$^{2+}$ or Zn$^{2+}$ ions was quantitatively analyzed by using an energy dispersive X-ray spectroscopy (EDS) and an inductively coupled plasma atomic emission spectroscopy (ICP-AES) (Supplementary Information Fig. S1). Conventional Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$...
(C-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$) nanoparticles were also explored for comparison. C-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$ nanoparticles obtained using a conventional experimental method showed similar particle size, size distribution and particle shape to those of T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$ nanoparticles (Supplementary Information Fig. S2). Figure 2c shows the direct current (DC) minor hysteresis loops of as-synthesized T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$ and C-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$ nanoparticles (solid state) measured at a sweeping field of $H_{\text{app}} = \pm 140$ Oe. The two nanoparticles did not exhibit any DC minor hysteresis indicating that the synthesized T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$ and C-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$ nanoparticles have typical superparamagnetic characteristics. However, as can be seen in Fig. 2d, a larger AC hysteresis loss was observed from the T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$ nanoparticles. This result indicates that T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$ nanoparticles are magnetically softer than that of C-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$ nanoparticles under AC magnetic field. Furthermore, it implies that T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$ nanoparticles would generate a higher AC magnetically-induced heating temperature since the larger AC hysteresis loss area of those indicating that it has a higher AC softness, which is directly related to the larger “Néel relaxation loss power”$^{22}$. Figure 2e shows the AC magnetically-induced heating temperature ($T_{\text{AC, mag}}$) of T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$ and C-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$ in solid state. As we expected from Fig. 2d, the T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$ nanoparticles had much higher $\Delta T_{\text{AC, mag}}$ compared to that of C-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$. Figure 2f shows the measured DC hysteresis loop of T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$@PEG (40 μg/100 μL D.I. water) nanofluids. The observed high mono-dispersity of T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$@PEG nanofluids can be confirmed from the DC magnetic hysteresis loop, because agglomerated nanoparticles in nanofluids can generally cause undesirable changes in dipole-dipole interactions or degradation of magnetic properties directly resulting in asymmetric hysteresis behavior$^{22,23}$. The measured hysteresis was symmetric and severe degradation was not observed. No severe magnetic degradation or no change of magnetic intrinsic properties compared to those of solid state indicating that the PEG coated T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$ SPNPs are well dispersed in the nanofluid and form chemically stable colloidal suspension. Furthermore, this well controlled coating status of T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$@PEG SPNPs is expected to improve the efficiency of the cellular uptake and the cell viability associated with cell cytotoxicity$^{24–26}$. 

Prior to controlling D value of the AC magnetic field during MNFH with RGCs-5 to study the effects of recovery time on the rate of cell death and the corresponding efficiency of the induction of HSP72, the $T_{\text{AC, mag}}$ and intrinsic loss power (ILP) of T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$@PEG SPNPs were measured in three different media (ethanol, D.I. water, and RGCs-5 cells) to explore AC self-heating characteristics of T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$@PEG SPNPs under different microenvironments. For this measurement, the micro-centrifuge tube containing the T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$@PEG SPNPs with ethanol, D.I. water, and RGCs-5, was placed at the center of AC magnetic coil (Fig. 3a and b). The concentration of the T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$@PEG nanofluid was 5 mg/mL and the applied $f_{\text{app}}$ and $H_{\text{app}}$ were fixed at a 110 kHz, and a 140 Oe, respectively. After the power is turned on, the $T_{\text{AC, mag}}$ of T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$@PEG nanofluids was rapidly increased and saturated at a 43 °C (in ethanol) and a 41.3 °C (in D.I. water) within 1000 sec. with different AC heating up rate due to the different specific heat capacities and
The viscosities of the two nanofluids (Fig. 3c). In addition, after the AC magnetic field was removed, $T_{AC,mag}$ was decreased sharply for both two nanofluids. To measure the $T_{AC,mag}$ of T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$@PEG SPNPs in RGCs-5, RGCs-5 were incubated with a 5 mg/mL (DMEM) of T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$@PEG nanofluid measured in ethanol and D.I. water. The $f_{appl}$ and $H_{appl}$ were 110 kHz, and 140 Oe, respectively, and the concentration was 5 mg/mL. AC magnetically-induced heating characteristics of RGCs-5 treated with a 500 μg/mL of T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$@PEG nanofluid. The $f_{appl}$ and $H_{appl}$ were 140 kHz, and 170 Oe, respectively. (e) ILP values of T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$@PEG nanofluids calculated based on the $T_{AC,mag}$ (c) and (d).

**Figure 3.** In vitro MNFH studies using T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$@PEG nanofluid for RGCs-5 cells. (a) An illustration of the in vitro experimental set-up. (b) A microcentrifuge tube containing RGCs-5 treated with T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$@PEG nanofluid with an inserted optical thermometer (OT) for measuring the $T_{AC,mag}$ during HSP72 induction. (c) AC magnetically-induced heating characteristics of T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$@PEG nanofluid measured in ethanol and D.I. water. The $f_{appl}$ and $H_{appl}$ were 110 kHz, and 140 Oe, respectively, and the concentration was 5 mg/mL. (d) AC magnetically-induced heating characteristics of RGCs-5 treated with a 500 μg/mL of T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$@PEG nanofluid. The $f_{appl}$ and $H_{appl}$ were 140 kHz, and 170 Oe, respectively. (e) ILP values of T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$@PEG nanofluids calculated based on the $T_{AC,mag}$ (c) and (d).
T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$@PEG SPNPs in different microenvironments (ethanol, D.I. water, and RGCs-5 cells) directly indicates that the contribution of "Néel" and "Brownian" relaxation heating power to the total heating power is dependent on the nanofluidic ambient environment. A higher viscosity resulted in a lower heating power due to the reduction of "Brownian relaxation loss power" caused by the increase of Brownian relaxation time. This indirectly implies that the "Néel relaxation loss power" would be dominant in characterizing the AC heat generation of superparamagnetic nanoparticles in intercellular or in-vivo hyperthermia 27,28. In addition, the higher ILP of T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$@PEG nanofluid allows us to apply it for a MNFH agent to systematically and readily control the D value (or $\tau_R$ and $\tau_H$) to adjust the induction characteristics during MNFH so that the highly efficient induction of HSP72 in RGCs-5 can be expected to be achieved.

After confirming the high AC magnetically-induced heating characteristics of T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$@PEG nanofluid, we conducted systematic studies about the effects of recovery time during MNFH on the characteristics of the cell death and the efficiency of the induction of HSP72 in RGCs-5. Figure 4a–d shows the D value controlled T$_{AC,mag}$ curves (or AC heating stress curves) of RGCs-5 pellet treated with T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$@PEG nanofluid (500 μg/mL). The D values of the AC magnetic field were systematically changed at a typical HSPs induction temperature of 40.5 °C ± 0.5 °C by adjusting the H$_{appl}$ ($\tau_H$: 170 Oe (40.5 °C ± 0.5 °C) and $\tau_C$: 100 Oe (~36 °C)) at the fixed f$_{appl}$ of 140 kHz. The HRI time in one cycle of the AC magnetic field was 600 sec and thus the corresponding $\tau_R$ values were 450 sec (D: 25%, $\tau_H$: 150 sec), 300 sec (D: 50%, $\tau_H$: 300 sec), 150 sec (D: 75%, $\tau_H$: 450 sec), and 0 sec (D: 100%, $\tau_H$: 1200 sec).

After MNFH was carried out at the different conditions of D values of AC magnetic field in RGCs-5, the Western blot analysis was carried out to identify the induction of HSP72 and subsequently, the dependence of HSP72 induction. In addition, the cell death rate depending on the D values of AC magnetic field was investigated by using optical microscope images of the stained RGCs-5. The inset image in Figure 4e shows the Western blot result of the RGCs-5 after MNFH. As can be seen in the Figure, a strong immunoreactivity for HSP72 was detected. Figure 4e–h show the images for the stained HSP72 and nuclei for investigating the dependence of HSP72 induction and the cell death rate on the controlling D value of the AC magnetic field treated with T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$@PEG. (i–l) the images of stained HSP72 and nuclei without T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$@PEG.
was monotonically increased by increasing the D value of applied AC magnetic field, but in contrast, it was also observed from the microscopic images that the cell survival rate (defined by “visible number of cells or nuclei”) was gradually decreased by increasing the D value of applied AC magnetic field (or AC heating stress). These results clearly illustrate that the change of D value during MNFH directly influence on the extent of the induction of HSP72 as well as the cell death behavior in RGCs-5 during MNFH induced heat shock protein process. In order to numerically analyze the effects of controlling D value of the applied magnetic field on the induction efficiency of HSP72, the relative numerical calculation methods were employed for quantitative analysis. First, the HSP72 induction rate (denoted by “RH”) of HSP72 was slightly decreased by increasing the D value during MNFH. However, it was also found that the HSP72 induction rate was monotonically increased by increasing the D value of applied AC magnetic field, but in contrast, it was also found that the HSP72 induction rate was slightly decreased by increasing the D value during MNFH. These results indicate that applying the appropriate or optimized τR during MNFH can improve the cell survival rate by allowing the cells to have the time to recover from the applied AC magnetic field. Thus, in order to achieve the most efficient HSP72 induction for clinical applications. It was experimentally demonstrated that the controlling τR during MNFH affects not only the cell death rate but also with enough recovery time (τR). These results indicate that applying the appropriate or optimized τR during MNFH can improve the η of HSP72 by minimizing the cell death caused by the cytotoxic effect of the heat. Furthermore, this study is expected to provide a useful solution for the safe and effective induction of HSP72 for the highly efficient ocular neuroprotection for glaucoma.

Table 1. The calculated results of cell death and HSP72 induction rate and induction efficiency of HSP72 after MNFH controlled the D value of the AC magnetic field. *P-value < 0.05 on student t-test.

| Duty cycle value (D) | Cell death rate (Mean ± SD) | HSP72 induction rate (Mean ± SD) | HSP72 induction efficiency (%) |
|----------------------|-----------------------------|----------------------------------|--------------------------------|
| 0.25                 | 22.1 ± 0.8*                 | 10.3 ± 0.5*                      | 46.6                           |
| 0.5                  | 30.0 ± 1.3*                 | 18.0 ± 0.7*                      | 60.0                           |
| 0.75                 | 53.0 ± 2.1*                 | 23.0 ± 1.1*                      | 43.4                           |
| 1.0                  | 65.4 ± 3.2*                 | 26.9 ± 1.3*                      | 41.1                           |

Conclusions

We investigated the effects of τR during MNFH on the induction rate of HSP72 and cell death behavior of RGCs-5 to achieve the most efficient η of HSP72 induction for clinical applications. It was experimentally demonstrated that the controlling τR during MNFH affects not only the cell death rate but also HSP72 induction rate. The cell death rate after MNFH was dramatically decreased by increasing the τR during MNFH. However, it was also found that the HSP72 induction rate was slightly decreased by increasing the τR. These results indicate that applying the appropriate or optimized τR during MNFH can improve the η of HSP72 by minimizing the cell death caused by the cytotoxic effect of the heat. Furthermore, this study is expected to provide a useful solution for the safe and effective induction of HSP72 for the highly efficient ocular neuroprotection for glaucoma.
Methods

Synthesis of conventional and magnetically tailored Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$ SPNPs and PEG coating for nanofluids. Fe (III) acetylacetonate (precursor, >99.9%), Mn (II) acetate tetrahydrate (99.9%), Zn acetate dihydrate (99.999%), Oleic acid (surfactant, 90%), Oleylamine (surfactant, 70%), 1,2-hexadecanediol (reductant, 90%), and benzyl ether (solvent, 99%) were purchased from Sigma-Aldrich to synthesize Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$ SPNPs. In order to coat the nanoparticles with PEG, methoxy-PEG-silane 500 Da, and triethylamine, which were purchased from Gelest Inc., and Sigma-Aldrich, respectively, were used. The conventional Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$ (C-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$) SPNPs and magnetically tailored Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$ (T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$) SPNPs were synthesized using a conventional high temperature thermal decomposition (HTTD) method, and a chemically and thermally modified HTTD method, respectively. To synthesize C-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$ SPNPs, Mn (II) (0.5 mmol), Zn (II) (0.5 mmol), Fe (III) (2 mmol), oleic acid (6 mmol), oleylamine (6 mmol), 1,2-hexadecanediol (10 mmol), and benzyl ether (20 mL) were mixed in a three-neck flask and magnetically stirred at room temperature. The mixed solutions were heated to 200 °C for 30 min (~6 °C/min, the first ramping up rate) and maintained for another 120 min (nucleation step). Then, the solutions were heated again up to 296 °C, which is a boiling point of benzyl ether, for 8 min (12 °C/min, the second ramping rate) and maintained for 60 min (growth step). While, for the T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$ SPNPs, the synthesis conditions were chemically and thermally tailored from the conventional HTTD process to control the concentration of cations and their distribution in A (tetrahedral) and B (octahedral)-sites of Fe$_2$O$_4$. To synthesize the T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$ SPNPs, Mn (II) (0.5 mmol), Zn (0.5 mmol), Fe (III) (2 mmol), oleic acid (6 mmol), oleylamine (6 mmol), 1,2-hexadecanediol (10 mmol), and benzyl ether (20 mL) were mixed in a three-neck flask and magnetically stirred at room temperature. The ramping up rate, and the heat treatment time in the nucleation process (process temperature: ~200 °C) were 11 °C/min and 60 min, respectively. Then, the reaction solutions were heated again up to 296 °C for 30 min (3.2 °C/min, the second ramping rate) and the heat treatment time in the growth process (process temperature: ~296 °C) was 46.5 min. After the heat treatment process, the mixed solution was cooled down to room temperature and ethanol (40 mL) was added to the mixed solution to rinse the synthesized nanoparticles. The rinsed nanoparticles were collected by centrifugation and then dried at room temperature. The synthesized T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$ nanoparticles were coated with PEG to form a nanofluid. For coating the PEG layer, the nanoparticles were first dispersed in toluene (7.5 mL), and then PEG (0.75 mL) and triethylamine (catalyst, 3.75 mL) were added to the toluene containing the nanoparticles. The mixed solution was shaken well for 24 hours at room temperature, and then the PEG coated nanoparticles were collected by centrifugation and dispersed in D.I. water.

Characterization and magnetic properties of C-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$ and T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$ nanoparticles. The size and morphology of the synthesized C-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$ and T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$ nanoparticles were analyzed using a transmission electron microscopy (TEM). The DC magnetic hysteresis loops of the uncoated (solid state) and PEG coated (fluid state) nanoparticles were measured using a vibrating sample magnetometer (VSM). In order to measure the magnetic properties of Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$@PEG nanofluid, we used a liquid VSM holder (liquid upper and bottom cup) at room temperature. For successful measurement, the liquid sample has to be encapsulated carefully without any air inside the capsules. A methoxy-PEG-silane 500 Da was used as a suitable surfactant to reduce aggregation of nanoparticles in fluidic state.

AC magnetically-induced heating temperature, $T_{AC, mag}$ and intrinsic loss power, ILP$_p$ of T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$@PEG nanoparticles. The $T_{AC, mag}$ of T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$@PEG nanofluids was measured in ethanol, D.I. water, and RGCS-5 using an AC magnetic field generation system consisting of AC coils, capacitors, DC power supplies, and wave generators (anytech. Korea). The applied frequency ($f_{appl}$), and $H_{appl}$ were determined based on the measured $T_{AC, mag}$ and using equation (2)32.

$$ILP[nHm^2kg^{-1}] = \frac{SLP[Wkg^{-1}]}{f[kHz]H^2[KA^{-1}]^2}$$

(2)

The SLP was determined based on the measured $T_{AC, mag}$ and using equation (3)33.

$$SLP[Wg^{-1}] = \frac{CVdt}{m}$$

(3)

(C: volumetric specific heat capacity, V$_s$: sample volume, m: mass of magnetic material, dt and dh: the initial slope of the graph of the change in temperature versus time)

Cell culture, in-vitro cytotoxicity assay, and cellular uptake. The rat RGCS-5 were cultured in Dulbecco Modified Eagle Medium (DMEM, Invitrogen, Carlsbad, CA) containing 10% fetal bovine serum (FBS, Introgen), 100 μg/ml penicillin/streptomycin (Invitrogen), and 2 mM glutamine (Invitrogen) in a humidified incubator with 5% CO$_2$ at 37 °C. The in-vitro cytotoxicity assay of RGCS with T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$@PEG nanoparticles was conducted at the concentration of 0, 1, 3, 5, 10, 30, 100, 250, and 500 μg/mL using a Cell Counting Kit-8 (CCK-8) assay (Fig. S3). The RGCS-5 cells were exposed to the nanoparticles for one day. For cellular uptake of T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$@PEG nanoparticles by RGCS-5, the RGCS-5 was differentiated with 1 μM staurosporine for 1 hour and incubated again with a 500 μg/mL of T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$@PEG nanoparticles in a 10 mL of DMEM for 24 hours. The RGCS-5 containing T-Mn$_{0.5}$Zn$_{0.5}$Fe$_2$O$_4$@PEG nanoparticles were washed with phosphate buffered saline (PBS) and trypsinized with trypsin-EDTA (Life technologies, USA) followed by addition of 100 μL of DMEM, and then collected in a microcentrifuge tube and centrifuged to form a cell pellet. The volume of the
microcentrifuge tube was 0.6 mL. The pellet size was 0.4 × 0.4 cm, when cell preparation was performed in a 0.6 mL tube.

Control of $\tau_R$ during MNFH with RGCs-5. An optical thermometer (thermal sensor tip, experimental group) was inserted in the RGCs-5. The thermometer probe tip was precisely located inside the cell pellet (Fig. S5) and were placed at the center of AC coil to apply the AC magnetic field for MNFH. The $\tau_R$ from AC magnetic field (AC heating stress) during MNFH was changed by controlling the D value of AC magnetic field in RGCs-5. The D value was defined as the ratio of the $\tau_R$ to the heat repetition interval (HRI = $\tau_R$ + $\tau_D$), as shown in Fig. 1(b). The D value was controlled from 25% (0.25) to 100% (1) by tuning the $H_{\text{appl}}$ ($\tau_D$: 170 Oe and $\tau_R$: 100 Oe) at the fixed $f_{\text{appl}}$ of 140 kHz during MNFH. RGCs-5 pellets without $T$-$\text{Mn}_0.5\text{Zn}_0.5\text{Fe}_2\text{O}_4@\text{PEG}$ nanoparticles were also prepared as a control group, and they were undergone the same AC magnetic field conditions as the experimental group done.

Induction and Identification of HSP72. At 24 hours after MNFH, the RGCs-5 were fixed in 10% formaldehyde for 10 min, and then the fixed RGCs-5 were washed with PBS-20 three times. In order to identify the induction of HSP72 and to study the induction behavior at the intercellular level, the RGCs incubated with nanofluid were collected in a microcentrifuge tube and centrifuged to form a cell pellet. The microcentrifuge tube containing the RGCs pellet was immersed in a hot water bath to make the temperature of RGCs with nanofluids keep in the range of 36 – 37°C. The microcentrifuge tube with an optical thermometer inserted in the RGCs was placed at the center of AC coil to apply AC magnetic field. The heating up rate of "AC magnetically-induced heating stress" of the nanofluids in RGCs was controlled by changing the strength of $H_{\text{appl}}$ in the biologically and physiologically safe range of 120 Oe ($H_{\text{appl}}$-$f_{\text{appl}}$: 1.34 × $10^4$ A m$^{-1}$ s$^{-1}$) – 160 Oe ($H_{\text{appl}}$-$f_{\text{appl}}$: 1.78 × $10^4$ A m$^{-1}$ s$^{-1}$) at the fixed frequency of 140 kHz. The $T_{AC,\text{mag}}$ of RGCs with nanofluids during HSPs induction process was kept at the temperature of 40.5°C ± 0.3°C for 900 sec. The induction of HSP72 in the RGCs-5 was confirmed by staining the cells. The HSP72 were stained by Anti-HSP72 (primary antibody, Enzo life sciences, USA) and Alexa fluor 488 goat anti-mouse IgG (secondary antibody, FITC, Fluorescein isothiocyanate, Life technologies, USA), and the nucleus were stained by DAPI (4′,6-diamidino-2-phenylindole, Sigma, USA). An Olympus IX51 microscope (OLYMPUS CORPORATION, Tokyo, Japan) was used at 400x magnification for image acquisition. Images were recorded with an DFC500 high-resolution digital camera and processed using LAS (LEICA Application Suite) ver 4.2 software (LEICA Company, Wetzlar, Germany). The induced HSP72 were also identified by employing Western blot analysis. For Western blot analysis, the collected RGCs-5 were lysed using a lysis buffer (Intron Biotechnology, Korea) and loaded onto a 12% SDS-polyacrylamide gel. Subsequently, they were transferred to Polyvinylidene fluoride membrane. The membrane was blocked by non-fat dry milk and incubated with primary antibody of HSP72 (1:1000, Enzo Lifesciences, USA) and β-actin antibody (1:1000, Sigma, USA). The membrane was washed with a Tris-buffered saline containing 0.1% Tween-20 and incubated in a goat anti-mouse IgG (1:5000, Santa Cruz, USA). The immunoblotting bands were detected by West-zol detection system (Intron Biotechnology, Korea).

Statistical Analysis. The efficiency and cell death rate data were expressed with mean values along with standard deviations from at least three repetitive experiments. The statistical analysis was done using Prism software 7.0 (GraphPad Software, Inc., San Diego, CA), and student’s t-test were used to compare the data in groups. ( *Represents *P < 0.05) All the experiments were repeated on separate days, and the data shown in this study are representative of all the repetitions.

References
1. Barbé, M. F., Tytell, M., Gower, D. J. & Welch, W. J. Hyperthermia protects against light damage in the rat retina. Science 241, 1817–1820 (1988).
2. Amin, V., Cumming, D. V. E. & Latchman, D. S. Over-expression of heat shock protein 70 protects neuronal cells against both thermal and ischaemic stress but with different efficiencies. Neurosci Lett 260, 45–48 (1996).
3. Caprioli, J., Kitano, S. & Morgan, J. E. Hyperthermia and hypoxia increase tolerance of retinal ganglion cells to anoxia and excitotoxicity. Invest Ophthalmol Vis Sci 37, 2376–2381 (1996).
4. Mizzen, L. A. & Welch, W. J. Characterization of the thermitolerant cell. I. Effects on protein synthesis activity and the regulation of heat-shock protein 70 expression. J Cell Biol 106, 1105–1116 (1988).
5. Sato, K., Saito, H. & Matsuki, N. HSP70 is essential to the neuroprotective effect of heat-shock. Brain Res 740, 117–123 (1996).
6. Dieing, A. et al. The effect of induced hyperthermia on the immune system. Prog Brain Res 162, 137–152 (2007).
7. Tanaka, Y., Kobayashi, K., Kita, M. & Hirocn, M. Expression of 47 kDa heat shock protein (HSP47) during development of mouse cornea. Exp Eye Res 63, 383–393 (1996).
8. Laiois, E., Rebyeka, I. M. & Prody, C. A. Characterization of cold-induced heat shock protein expression in neonatal rat cardiac myocytes. Mol Cell Biochem 173, 153–159 (1997).
9. Herdt, R., Dutz, S., Müller, R. & Zeisberger, M. Magnetic particle hyperthermia: nanoparticle magnetism and materials development for cancer therapy. J Phys Condens Matter 18, S2919–2934 (2006).
10. Pankhurst, Q. A., Connolly, J., Jones, S. K. & Dobson, J. Applications of magnetic nanoparticles in biomedicine. J Phys D: Appl Phys 36, R167–181 (2003).
11. Berry, C. C. & Curtis, A. S. G. Functionalisation of magnetic nanoparticles for applications in biomedicine. J Phys D: Appl Phys 36, R198–206 (2003).
12. Donnelly, T. J., Sievers, R. E., Vusser, E. L. J., Welch, W. J. & Wolfe, C. L. Heat shock protein induction in rat hearts. A role for improved myocardial salvage after ischemia and reperfusion? Circulation 85, 769–778 (1992).
13. Kim, J. M., Park, K. H., Kim, Y. J., Park, H. J. & Kim, D. M. Thermal injury induces heat shock protein in the optic nerve head in vivo. Invest Ophthalmol Vis Sci 47, 4888–4894 (2006).
14. Wältner, W. & Stein, U. Heat-responsive gene expression for gene therapy. Adv Drug Deliv Rev 61, 641–649 (2009).
15. Dewhurst, M. W., Lee, C.-T. & Ashcraft, K. A. The future of biology in driving the field of hyperthermia. Int J Hyperthermia 32, 4–13 (2016).
16. Ma, J. et al. Magnetic nanoparticle clusters radiosensitise human nasopharyngeal and lung cancer cells after alternating magnetic field treatment. Int J Hyperthermia 31, 800–812 (2015).
17. Chudzik, B. et al. Effectiveness of magnetic fluid hyperthermia against candida albicans cells. *Int J Hyperthermia* **32**, 842–857 (2016).
18. Hilger, I. *In vivo* applications of magnetic nanoparticle hyperthermia. *Int J Hyperthermia* **29**, 828–834 (2013).
19. Vidair, C. & Dewey, W. C. Two distinct modes of hyperthermic death. *Radiat Res* **116**, 157–171 (1988).
20. Dewhirst, M. W., Viglianti, B. L., Lora-Michiels, M., Hanson, M. & Hoopes, P. J. Basic principles of thermal dosimetry and thermal thresholds for tissue damage from hyperthermia. *Int J Hyperthermia* **19**, 267–94 (2003).
21. Jeun, M. et al. Effects of Mn concentration on the ac magnetically induced heating characteristics of superparamagnetic Mn$_x$Zn$_{1-x}$Fe$_2$O$_4$ nanoparticles for hyperthermia. *App Phys Lett* **96**, 202511–202513 (2010).
22. Jonsson, T. et al. Aging in a magnetic particle system. *Phys Rev Lett* **75**, 4138–4141 (1995).
23. Jeun, M. et al. Physical parameters to enhance ac magnetically induced heating power of ferrite nanoparticles for hyperthermia in nanomedicine. *IEEE Trans Nanotech* **12**, 314–322 (2013).
24. Gutiérrez, L. et al. AC magnetic susceptibility study of *in vivo* nanoparticle biodistribution. *J Phys D: Appl Phys* **44**, 255002–255009 (2011).
25. Zorko, M. & Langel, U. Cell-penetrating peptides: mechanism and kinetics of cargo delivery. *Adv Drug Deliv Rev* **57**, 529–45 (2005).
26. Zhang, Y., Kohler, N. & Zhang, M. Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. *Biomaterials* **23**, 1553–1561 (2002).
27. Cabrera, D., Camarero, J., Ortega, D. & Teran, F. J. Influence of the aggregation, concentration, and viscosity on the nanomagnetism of iron oxide nanoparticle colloids for magnetic hyperthermia. *J Nanopart Res* **17**, 121 (2015).
28. Périgo, E. A. et al. Fundamentals and advances in magnetic hyperthermia. *App Phys Rev* **2**, 041302 (2015).
29. Pulda, S., Gorman, A. M., Hori, O. & Samali, A. Cellular Stress Responses: Cell Survival and Cell Death. *Int J Cell Biol* **214074**, 1–23 (2010).
30. Jolly, C. & Morimoto, R. J. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. *J Natl Cancer Inst* **92**, 1564–1572 (2000).
31. Sun, S. et al. Monodisperse MFe$_2$O$_4$ (M = Fe, Co, Mn) nanoparticles. *J Am Chem Soc* **126**, 273–279 (2004).
32. Wildeboer, R. R., Southern, P. & Pankhurst, Q. A. On the reliable measurement of specific absorption rates and intrinsic loss parameters in magnetic hyperthermia materials. *J Phys D: Appl Phys* **47**, 495003 (2014).
33. Hosono, T. et al. Synthesis of maghnite nanoparticles for AC magnetic heating. *J Magn Magn Mater* **321**, 3019–3023 (2009).

**Acknowledgements**

Dr. J.-t. Jang and Prof. J. W. Jeoung contributed equally to this work. This work was supported by the Korea Health Technology R&D Project, Ministry of Health & Welfare, Korea under Grant No. HI13C2061.

**Author Contributions**

S. Bae, K.H. Park, and S.H. Paek conceived and designed the experiments, reviewed the manuscript. J. Jang, J.W. Jeoung and S. Bae analysed the acquired results and wrote the manuscript text. J.H. Park, W.J. Lee, Y.J. Kim, M. Kim, and J. Lee performed all the cellular experiments. J. Seon synthesized nanoparticles.

**Additional Information**

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-017-14348-2.

**Competing Interests:** The authors declare that they have no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2017